Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA vs KERENDIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.
Relief of moderate to moderately severe pain
To reduce the risk of sustained e GFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
The terminal elimination half-life is approximately 2–4 hours in healthy subjects. In patients with renal impairment, the half-life may be prolonged up to 6–8 hours, allowing for once-daily dosing in chronic kidney disease.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily metabolized by CYP3A4 (≈90%) and to a lesser extent by CYP2C8 (≈10%). No active metabolites.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Approximately 80% of the dose is eliminated via feces (primarily as unchanged drug) and ~20% via urine (mostly as metabolites). Renal excretion of unchanged drug is minimal (less than 1%).
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Approximately 92% bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
The apparent volume of distribution is approximately 50 L (about 0.7 L/kg in a 70 kg adult), indicating moderate tissue distribution, likely into kidney and heart tissues.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
Oral bioavailability is about 90–95% in healthy subjects, indicating nearly complete absorption after oral administration. Food does not significantly affect absorption.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
e GFR 25-59 m L/min/1.73 m²: Initiate 10 mg once daily; continue 10 mg if tolerated. e GFR <25 m L/min: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Child-Pugh B (moderate impairment): 10 mg once daily. Child-Pugh C (severe impairment): Not recommended.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Safety and efficacy not established in pediatric patients.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
No specific dose adjustment required; monitor renal function closely.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
No FDA boxed warning.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hyperkalemia: Monitor serum potassium levels; may require dose adjustment or discontinuation.,Hypotension: Risk increased in patients with volume depletion or concomitant antihypertensive therapy.,Acute kidney injury: Monitor renal function; consider temporary discontinuation in setting of significant renal impairment.,Hepatic impairment: Not recommended in patients with severe hepatic impairment (Child-Pugh C).
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir).,Addison's disease (adrenal insufficiency).,Serum potassium > 5.0 m Eq/L at initiation.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase finerenone exposure. No other food interactions noted.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiovascular, skeletal) were observed at maternal exposures below the maximum recommended human dose. In rabbits, increased post-implantation loss and decreased fetal weights occurred. There are no adequate human studies. Use is contraindicated in pregnancy. Avoid in women of childbearing potential not using effective contraception.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No data on presence in human milk, effects on breastfed infant, or milk production. Excreted in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy and for 1 week after last dose.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Kerendia is contraindicated in pregnancy. No dose adjustments are provided due to lack of human data; use is not recommended. Pharmacokinetic changes in pregnancy are unknown, but dose modifications are not applicable as therapy should be discontinued if pregnancy occurs.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Monitor serum potassium closely, especially in patients with e GFR <30 m L/min/1.73m² or baseline K+ >5.0 m Eq/L. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). Contraindicated with concomitant mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone). Use caution with moderate CYP3A4 inhibitors (e.g., erythromycin, verapamil) and moderate CYP3A4 inducers (e.g., rifampin, phenytoin). Assess e GFR and serum potassium before initiation and at 1 month after starting or adjusting dose.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
Take this medication exactly as prescribed, usually once daily with or without food.,Do not use potassium supplements or salt substitutes containing potassium without consulting your doctor.,Report symptoms of hyperkalemia (e.g., muscle weakness, fatigue, palpitations, numbness) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Inform all healthcare providers that you are taking KERENDIA (finerenone).,Do not stop taking KERENDIA without talking to your doctor.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA vs KERENDIA, answered by our medical review team.
ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. KERENDIA is a Mineralocorticoid Receptor Antagonist that works by Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA and KERENDIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. The standard adult dose of KERENDIA is: 10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA and KERENDIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . KERENDIA is classified as Category C. Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiov. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.